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Corrado Tamburino, MD, PHD*
Catania, Italy; New York, New York; Massy, France; and Jacksonville, Florida
Objectives The purpose of this study was to determine the safety and efficacy of percutaneous coronary intervention
(PCI) compared with coronary artery bypass graft (CABG) in patients with left main coronary artery (LMCA)
disease.
Background Previous meta-analyses of PCI versus CABG in LMCA disease mainly included nonprospective, observational
studies. Several new randomized trials have recently been reported.
Methods We identified 1,611 patients from 4 randomized clinical trials for the present meta-analysis. The primary end-
point was the 1-year incidence of major adverse cardiac and cerebrovascular events (MACCE), defined as death,
myocardial infarction (MI), target vessel revascularization (TVR), or stroke.
Results PCI was associated with a nonsignificantly higher 1-year rate of MACCE compared with CABG (14.5% vs.
11.8%; odds ratio [OR]: 1.28; 95% confidence interval [CI]: 0.95 to 1.72; p  0.11), driven by increased TVR
(11.4% vs. 5.4%; OR: 2.25; 95% CI: 1.54 to 3.29; p  0.001). Conversely, stroke occurred less frequently
with PCI (0.1% vs. 1.7%; OR: 0.15; 95% CI: 0.03 to 0.67; p  0.013). There were no significant differences
in death (3.0% vs. 4.1%; OR: 0.74; 95% CI: 0.43 to 1.29; p  0.29) or MI (2.8% vs. 2.9%; OR: 0.98; 95% CI:
0.54 to 1.78; p  0.95).
Conclusions In patients with LMCA disease, PCI was associated with nonsignificantly different 1-year rates of MACCE, death,
and MI, a lower risk of stroke, and a higher risk of TVR compared with CABG. (J Am Coll Cardiol 2011;58:
1426–32) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.005Current guidelines recommend percutaneous coronary in-
tervention (PCI) of the left main coronary artery (LMCA)
with stents as a Class IIa or IIb alternative to coronary artery
bypass graft (CABG) in patients with conditions that are
associated with a low risk of PCI procedural complications
and/or increased risk of adverse surgical outcomes (1–3).
These recommendations carry a B level of evidence, indi-
cating the lack of data derived from multiple randomized
clinical trials (RCTs) or meta-analyses (3). In fact, when the
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honoraria/lecture fees from Medtronic, Abbott Vascular, and Stentys. All other
authors have reported that they have no relationships relevant to the contents of this
paper to disclose.Manuscript received May 7, 2011; revised manuscript received June 24, 2011,
accepted July 5, 2011.guidelines were published, only a single small randomized
study (4) and a pre-specified subanalysis from a large RCT
of stents versus surgery (5) were available. This lack of
randomized data has prompted an overemphasis on pooled
observational studies (6,7). Since the publication of the
latest guidelines, 2 new RCTs have been reported that
compared PCI versus CABG in patients with LMCA
disease (8,9). We therefore performed an up-to-date meta-
analysis of data from all RCTs.
Methods
Literature search. We searched MEDLINE and Co-
chrane databases from January 1980 to April 2011 using
Internet-based search engines. The terms used for research
included “left main,” “percutaneous coronary intervention,”
“stent(s),” and “coronary artery bypass graft.” Furthermore,
we searched reference lists of relevant studies, reviews,
editorials, letters, and meeting abstracts. We restricted our
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September 27, 2011:1426–32 PCI Versus CABG in Left Main Diseaseanalysis to prospective RCTs or pre-specified subanalyses
from RCTs that met all of the following inclusion criteria:
1) study population of LMCA disease; 2) randomization to
PCI versus CABG; and 3) both safety and efficacy outcomes
were reported. The quality of the identified studies was
assessed to ensure minimization of bias. In detail, we
evaluated information regarding control for confounders,
measurement of exposure, completeness of follow-up, and
blinding. No formal scoring system was used. Reviewers
were not blinded to journal, authors, or institution of
publication.
Data extraction. All data were extracted independently by
2 evaluators (D.C. and C.T.); discrepancies were resolved by
consensus. The following outcomes were extracted: major
adverse cardiac and cerebrovascular events (MACCE, de-
fined as the composite of death, myocardial infarction [MI],
stroke [cerebrovascular accident (CVA)], or target vessel
revascularization [TVR]), all-cause death, MI, CVA, and
TVR. We restricted the follow-up period to 1 year. The
clinical endpoint definitions were similar among the trials.
Statistical analysis. Data were analyzed according to
intention to treat. The results of all studies were com-
bined using a random-effects model to minimize heter-
ogeneity between groups and confirmed by a fixed-effects
model to avoid overweighting of small studies. A 2-tailed
alpha of 5% was used for hypothesis testing. Statistical
heterogeneity was assessed with Cochran Q via a chi-
square test and quantified with the I2 test. The influence
f single trials was examined by excluding individual
tudies, and testing for systematic bias was performed
sing funnel plots and Begg’s test. Exploratory bivariate
eta-regressions were performed to assess heterogeneous
tudy effects. Statistical analysis was performed using
omprehensive Meta-Analysis version 2.0 (Biostat, Engle-
ood, New Jersey).
esults
earch results. As shown in Figure 1, 254 potentially
ligible studies were identified, 4 of which met the pre-
pecified inclusion criteria (Tables 1 and 2). Three studies
ere RCTs comparing PCI and CABG in LMCA disease
4,8,9). One study was a pre-specified subanalysis of pa-
ients with LMCA disease from the SYNTAX (Synergy
etween PCI With Taxus and Cardiac Surgery) trial (5,10).
f 1,611 randomized patients, 809 were assigned to PCI
nd 802 were assigned to CABG. First-generation drug-
luting stents (DES) were implanted in 96% of PCI
atients, and a left anterior internal mammary artery graft to
he left anterior descending artery was used in 95% of
ABG patients. Distal LMCA involvement was observed
n 64% of cases. The mean SYNTAX score ranged from 24
o 30, and the mean logistic EuroSCORE ranged from
.5% to 3.9%. Complete revascularization was achieved in
1% and 76% of patients treated with PCI and CABG,
espectively.utcomes. One-year outcomes
re listed in Table 3. There was a
onsignificant trend toward a
igher risk of MACCE with
CI versus CABG (14.5% vs.
1.8%; odds ratio [OR]: 1.28;
5% confidence interval [CI]:
.95 to 1.72; p  0.11) (Fig. 2),
ith no heterogeneity (I2  0%;
p  0.29) or systematic bias ap-
arent across the studies (p 
.17). The exclusion of the study
rom Boudriot et al. (8), which
id not include CVA among
ACCE, did not significantly
ffect the MACCE estimate
OR: 1.25; 95% CI: 0.90 to 1.72;
 0.18). None of the other
tudies was found to unduly in-
uence the MACCE estimate.
We were not able to separate
omposite death/MI/CVA
rom MACCE from the study
y Buszman et al. (4), and the study from Boudriot et al.
8) did not report CVA. Thus, death/MI/CVA estimates
re drawn from SYNTAX (5) and PRECOMBAT (Pre-
ier of Randomized Comparison of Bypass Surgery
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CI  confidence interval
CVA  cerebrovascular
accident
DES  drug-eluting stent(s)
LMCA  left main coronary
artery
MACCE  major adverse
cardiac and
cerebrovascular event(s)
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
RCT  randomized clinical
trial
TVR  target vessel
revascularization
Figure 1 Flow Diagram of the Study Selection Process
CABG  coronary artery bypass graft; PCI  percutaneous coronary intervention.
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PCI Versus CABG in Left Main Disease September 27, 2011:1426–32Versus Angioplasty Using Sirolimus-Eluting Stent in
Patients With Left Main Coronary Artery Disease) (9),
the 2 largest studies. The 1-year composite of death/MI/
CVA occurred in 5.3% of PCI and 6.8% of CABG
patients (OR: 0.77; 95% CI: 0.48 to 1.22; p  0.26) (Fig.
2), with no heterogeneity (I2  0%; p  0.84).
Death at 1 year occurred in 3.0% and 4.1% of PCI and
ABG patients, respectively (OR: 0.74; 95% CI: 0.43 to
.29; p  0.29) (Fig. 3), with no heterogeneity (I2  0%;
p  0.58) or systematic bias (p  0.09). The 1-year rates
of MI were 2.8% and 2.9% in PCI and CABG patients,
respectively (OR: 0.98; 95% CI: 0.54 to 1.78; p  0.95)
(Fig. 3), with no heterogeneity (I2  0%; p  0.79) or
systematic bias (p  0.17). CVA at 1 year occurred
ignificantly less frequently with PCI compared with
ABG (0.1% vs. 1.7%; OR: 0.15; 95% CI: 0.03 to 0.67;
 0.013) (Fig. 3), with no significant heterogeneity
I2  0%; p  0.94) or systematic bias (p  1.00). The
CVA risk reduction with PCI versus CABG lost its
statistical significance after excluding the SYNTAX
LMCA subgroup (5) from the meta-analysis, although
the OR was comparable (OR: 0.20; 95% CI: 0.02 to 1.71;
p  0.14). PCI was associated with a higher 1-year rate
of TVR compared with that for CABG (11.4% vs. 5.4%;
OR: 2.25; 95% CI: 1.54 to 3.29; p  0.001) (Fig. 3), with
o heterogeneity (I2  0%; p  0.72) or systematic bias
p  0.31).
eta-regression and subgroup analyses. Meta-regression
nalysis did not disclose statistically significant interactions
or any of the previously mentioned outcomes between PCI
ersus CABG and the log-OR of the number of enrolled
Studies Included in the Meta-AnalysisTable 1 Studies Included in the Meta-Analysis
Study/First Author
(Ref. #) Year Design N
PCI,
n
LEMANS (4) 2008 RCT 105 52
SYNTAX Left Main (5) 2009 Pre-specified subanalysis
from RCT
705 357
Boudriot et al. (8) 2010 RCT 201 100
PRECOMBAT (9) 2011 RCT 600 300
CABG  coronary artery bypass graft; CVA  cerebrovascular accident; DES  drug-eluting s
internal mammary artery; MI  myocardial infarction; PCI  percutaneous coronary interventi
Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease; RCT randomized
Surgery.
Patients and Procedural Characteristics of Included StudiesTable 2 Patients and Procedural Characteristics of Included St
Study/First Author
(Ref. #)
Age,
yrs
Male,
%
Diabetes,
%
Distal LMCA
Disease, %
Dis
LEMANS (4) 61 67 18 58
SYNTAX Left Main (5) 65 74 25 61 1
Boudriot et al. (8) 68 75 36 71 2
PRECOMBAT (9) 62 77 32 65 1LMCA  left main coronary artery; other abbreviations as in Table 1.atients, diabetes, distal LMCA involvement, mean
YNTAX score, mean logistic EuroSCORE, or com-
lete revascularization (all p  nonsignificant).
The SYNTAX (5) and PRECOMBAT (9) trials re-
ported MACCE stratified by number of vessels involved. In
pooled analyses of these 2 studies, the 1-year MACCE rates
were nonsignificantly different with PCI compared with
those for CABG for isolated LMCA disease (OR: 0.66;
95% CI: 0.18 to 2.40; p  0.53), LMCA plus 1-vessel
disease (OR: 0.58; 95% CI: 0.22 to 1.51; p  0.26), and
LMCA plus 2-vessel disease (OR: 1.28; 95% CI: 0.74 to
2.23; p  0.38), but higher with PCI in patients with
LMCA plus 3-vessel disease (OR: 1.80; 95% CI: 1.06 to
3.07; p  0.03) (Figs. 4 and 5).
Discussion
In this meta-analysis of RCTs involving patients with
LMCA disease, PCI was found to be nonsignificantly
different than CABG with respect to composite MACCE
at 1-year follow-up. In addition, the 2 groups had similar
rates of the combined endpoint of death/MI/CVA and of
the individual components of death and MI. However,
CVA occurred less frequently and TVR occurred more
frequently in patients treated with PCI compared with
CABG.
In a previous meta-analysis from Naik et al. (11) of 10
studies (8 of which were registries), PCI was associated
with a nonsignificant 16% reduction in 1-year MACCE
compared with CABG, with an approximately 4-fold
, CABG,
n
LIMA
to LAD, % Primary Outcome
53 81 Cardiac death, MI, CVA, repeat revascularization,
and/or acute/subacute in-stent thrombosis
348 97 All-cause death, CVA, MI, and repeat
revascularization
101 99 All-cause death, MI, and repeat revascularization
300 94 All-cause death, CVA, MI, and
repeat revascularization
LAD  left anterior descending; LEMANS  Left Main Coronary Artery Stenting; LIMA  left
ECOMBAT  Premier of Randomized Comparison of Bypass Surgery Versus Angioplasty Using
trial; SYNTAX Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac
of
Vessels,
/3, %
SYNTAX Score,
Mean
Logistic
EuroSCORE,
Mean %
Complete Revascularization,
Overall/PCI/CABG, %
3/68 25 3.4 84/79/89
31/36 30 3.9 68/65/73
27/14 24 2.5 98/98/97
32/41 25 2.7 69/68/70DES
%
35
100
100
100
tent(s);
on; PRudies
No.
eased
0/1/2
0/9/2
3/20/
9/31/
0/17/
d cereb
1429JACC Vol. 58, No. 14, 2011 Capodanno et al.
September 27, 2011:1426–32 PCI Versus CABG in Left Main Diseaseincreased risk of TVR and no differences in mortality.
The lack of randomization in the majority of studies
resulted in only moderate internal validity, with moder-
ate/high chance for selection and attrition bias in 30% of
studies included and moderate performance and detec-
tion bias in all of them. Reliance on registries can lead to
incorrect conclusions because of the influence of unas-
sessed confounding variables (e.g., comorbidities, termi-
nal illness, low socioeconomic status); only randomiza-
tion can provide an unbiased estimation of the effects of
1-Year Outcomes in Left Main Patients Revascularized by PCI or CTable 3 1-Year Outcomes in Left Main Patients Revascularized
Endpoint
PCI
(n  809)
CABG
(n  802)
Abso
MACCE 14.5 (117/807) 11.8 (93/790) 2.7
Death/MI/CVA 5.3 (35/655) 6.8 (43/636) 1.5
Death 3.0 (24/807) 4.1 (32/790) 1.1
MI 2.8 (23/807) 2.9 (23/790) 0.1
CVA 0.1 (1/707) 1.7 (12/689) 1.6
TVR 11.4 (92/807) 5.4 (43/790) 6.0
Values are % (n/N) unless otherwise indicated.
CI  confidence interval; CVA  cerebrovascular accident; MACCE  major adverse cardiac an
Model Study name Statistics for each study
Odds Lower Upper 
ratio limit limit p-Value
LEMANS 1.368 0.579 3.229 0.475
SYNTAX lef t main 1.181 0.774 1.801 0.440
Boudriot et al. 1.458 0.686 3.098 0.327
PRECOMBAT 1.328 0.725 2.436 0.359
Fixed 1.276 0.950 1.715 0.106
Random 1.276 0.950 1.715 0.106
Major Adverse Cardiac a
Model Study name Statistics for each study
Odds Lower Upper 
ratio limit limit p-Value
SYNTAX lef t main 0.745 0.430 1.291 0.294
PRECOMBAT 0.828 0.352 1.946 0.664
Fixed 0.769 0.484 1.220 0.264
Random 0.769 0.484 1.220 0.264
Death, Myocardia
Pooled estimate
Pooled estimate
Pooled estimate
Pooled estimate
I2 = 0%
I2 = 0%
Figure 2 Effect of PCI on MACCE and the Composite of Death,
CI  confidence interval; LEMANS  Left Main Coronary Artery Stenting; MACCE 
COMBAT  Premier of Randomized Comparison of Bypass Surgery Versus Angiopl
SYNTAX  Synergy Between Percutaneous Coronary Intervention With Taxus and Ca treatment (12). Importantly, our meta-analysis included
only randomized data from 4 trials, making the risk of
residual confounding unlikely. The present study might
also be more reflective of current treatment practice than
the earlier meta-analysis (11) because 96% of PCI pa-
tients received DES and 95% of CABG patients were
revascularized with a left anterior internal mammary
artery graft.
The SYNTAX (5) and PRECOMBAT (9) trials were
designed as noninferiority trials and were individually un-
CI or CABG
ifference
CI)
Number Needed
to Treat
Number Needed
to Harm p Value
to 6.0) — 37 0.11
to 1.2) 67 — 0.26
to 0.8) 91 — 0.29
to 1.6) 1,000 — 0.95
to0.6) 63 — 0.013
8.7) — 17 0.001
rovascular event(s); TVR  target vessel revascularization; other abbreviations as in Table 1.
ts / Total Odds ratio and 95% CI
CABG
2 13 / 53
5 46 / 336
0 14 / 101
0 20 / 300
0.01 0.1 1 10 100
Favors PCI Favors CABG
Cerebrovascular Events
ts / Total Odds ratio and 95% CI
CABG
5 31 / 336
0 12 / 300
0.01 0.1 1 10 100
Favors PCI Favors CABG
farction or Stroke
or Stroke
r adverse cardiac and cerebrovascular event(s); MI  myocardial infarction; PRE-
sing Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease;
Surgery; other abbreviations as in Figure 1.ABGby P
lute D
(95%
(0.6
(4.1
(3.0
(1.8
(2.9
(3.3 toEven
PCI
16 / 5
56 / 35
19 / 10
26 / 30
nd 
Even
PCI
25 / 35
10 / 30
l In
MI,
majo
asty U
ardiac
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PCI Versus CABG in Left Main Disease September 27, 2011:1426–32Model Study name Statistics for each study Events / Total Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value PCI CABG
LEMANS 0.240 0.026 2.225 0.209 1 / 52 4 / 53
SYNTAX lef t main 0.944 0.454 1.963 0.878 15 / 355 15 / 336
Boudriot et al. 0.392 0.074 2.069 0.270 2 / 100 5 / 101
PRECOMBAT 0.745 0.255 2.173 0.590 6 / 300 8 / 300
Fixed 0.741 0.427 1.284 0.285
Random 0.741 0.427 1.284 0.285
0.01 0.1 1 10 100
Favors PCI Favors CABG
Death
Model Study name Statistics for each study Events / Total Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value PCI CABG
LEMANS 0.327 0.033 3.248 0.340 1 / 52 3 / 53
SYNTAX lef t main 1.015 0.482 2.136 0.969 15 / 355 14 / 336
Boudriot et al. 1.010 0.199 5.129 0.990 3 / 100 3 / 101
PRECOMBAT 1.338 0.297 6.029 0.705 4 / 300 3 / 300
Fixed 0.981 0.541 1.781 0.950
Random 0.981 0.541 1.781 0.950
0.01 0.1 1 10 100
Favors PCI Favors CABG
Myocardial Infarction
Model Study name Statistics for each study Events / Total Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value PCI CABG
LEMANS 0.196 0.009 4.187 0.297 0 / 52 2 / 53
SYNTAX left main 0.116 0.014 0.931 0.043 1 / 355 8 / 336
PRECOMBAT 0.199 0.009 4.156 0.298 0 / 300 2 / 300
Fixed 0.150 0.033 0.671 0.013
Random 0.150 0.033 0.671 0.013
0.01 0.1 1 10 100
Favors PCI Favors CABG
Stroke
Model Study name Statistics for each study Events / Total Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value PCI CABG
LEMANS 3.892 1.297 11.683 0.015 15 / 52 5 / 53
SYNTAX lef t main 2.072 1.215 3.532 0.007 45 / 355 22 / 336
Boudriot et al. 2.578 0.948 7.006 0.063 14 / 100 6 / 101
PRECOMBAT 1.851 0.840 4.079 0.127 18 / 300 10 / 300
Fixed 2.246 1.537 3.282 0.000
Random 2.246 1.537 3.282 0.000
0.01 0.1 1 10 100
Favors PCI Favors CABG
Repeat Revascularization
Pooled estimate
Pooled estimate
I2 = 0%
Pooled estimate
Pooled estimate
I2 = 0%
Pooled estimate
Pooled estimate
I2 = 0%
Pooled estimate
Pooled estimate
I2 = 0%
Figure 3 Effect of PCI on Death, MI, Stroke, and Repeat Revascularization
Pooled odds ratios are from fixed and random models. Abbreviations as in Figures 1 and 2.
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September 27, 2011:1426–32 PCI Versus CABG in Left Main Diseasederpowered for the composite rate of death/MI/CVA. Even
for MACCE, wide noninferiority margins (6.6% to 7.0%)
were necessary. In the present 1,611-patient meta-analysis,
a nonsignificant 2.7% treatment effect in favor of CABG
was evident. However, CVA was more frequent with
CABG, whereas TVR was more frequent with PCI. Many
clinicians believe that TVR is of less clinical importance
than death, MI, or stroke, arguably being more comparable
to numerous other adverse outcomes such as bleeding, renal
failure, or atrial fibrillation. The present study may thus be
informative to guide future trials comparing PCI and
CABG for LMCA disease with a more relevant endpoint,
such as the composite of death/MI/CVA. In the EXCEL
Figure 4 Effect of PCI on MACCE Stratified by Burden of Coron
Pooled odds ratios are from fixed and random models. LMCA  left main coronary
Figure 5 Differences in 1-Year MACCE Between PCI and CABG
SYNTAX Left Main and PRECOMBAT Studies After Str
Abbreviations as in Figures 1, 2, and 4.(Evaluation of Xience Prime or Xience V Versus CABG for
Effectiveness of Left Main Revascularization) trial, approx-
imately 2,600 patients with left main disease and SYNTAX
score 32 will be randomized to stent implantation with
the second-generation DES Xience stent (Abbott Vascular,
Santa Clara, California) or CABG. Of note, EXCEL is
including only patients with mild to moderate anatomic
complexity (SYNTAX score 32), for which the advan-
tages of CABG over PCI may be less evident (13). The
SYNTAX score roughly correlates with the extent of
coronary atherosclerosis (14), and our meta-analysis sup-
ports revascularization by CABG in patients with 3-vessel
disease.
rtery Disease
; other abbreviations as in Figures 1 and 2.
e Pooled Analysis of the
ation by Burden of Coronary Artery Diseaseary A
arteryin th
atific
d
a
m
p
a
o
w
p
t
o
t
p
C
F
w
L
t
w
C
r 1
1
1
1
1
1
1432 Capodanno et al. JACC Vol. 58, No. 14, 2011
PCI Versus CABG in Left Main Disease September 27, 2011:1426–32Study limitations. Variation in study design, endpoint
efinitions, and possible publication bias are limitations of
ll meta-analyses. Similarly, meta-regressions are prone to
isleading results (15). Even with 1,611 patients in the
resent study, our analysis cannot exclude small differences
mong the procedures. The present study reflects the
utcomes that may be expected when comparing CABG
ith first-generation DES. Of note, both PCI and CABG
rocedures continue to improve over time. Finally, because
he long-term advantage of CABG over PCI may accrue
ver time, a fair assessment of the 2 revascularization
echniques is likely to require longer follow-up than in the
resent study.
onclusions
rom the available RCT data, no significant differences
ere present between PCI and CABG in patients with
MCA disease for the occurrence of 1-year MACCE and
he component endpoints of death or MI. However, PCI
as associated with higher rates of TVR but with fewer
VAs compared with CABG. Based on the present study,
evision of the guidelines regarding left main PCI (1,2) is
warranted, raising the level of evidence of current recom-
mendations from B to A.
Reprint requests and correspondence: Dr. Davide Capodanno,
Ferrarotto Hospital, Via Citelli 6, 95124 Catania, Italy. E-mail:
dcapodanno@gmail.com.
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